• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射和口服给药后磺吡酮的动力学

Sulfinpyrazone kinetics after intravenous and oral administration.

作者信息

Lecaillon J B, Souppart C, Schoeller J P, Humbert G, Massias P

出版信息

Clin Pharmacol Ther. 1979 Nov;26(5):611-7. doi: 10.1002/cpt1979265611.

DOI:10.1002/cpt1979265611
PMID:498704
Abstract

Sulfinpyrazone kinetics has been investigated after intravenous and oral doses. They may be described by a 3-compartment open model. In the body about half the drug is in the plasma or in interstitial fluids, which equilibrated with plasma. Most of the rest is in an extravascular compartment, from which it easily diffuses back to the plasma. About 3% of the dose is still in the body after 24 hr and is located mainly in a deep compartment. After oral administration, sulfinpyrazone is quickly absorbed, largely from the stomach.

摘要

已对静脉注射和口服剂量后的磺吡酮动力学进行了研究。它们可用三室开放模型来描述。在体内,约一半的药物存在于血浆或与血浆平衡的组织间液中。其余大部分存在于血管外隔室,药物很容易从该隔室扩散回血浆。给药24小时后,约3%的剂量仍存在于体内,主要位于深部隔室。口服给药后,磺吡酮吸收迅速,主要从胃吸收。

相似文献

1
Sulfinpyrazone kinetics after intravenous and oral administration.静脉注射和口服给药后磺吡酮的动力学
Clin Pharmacol Ther. 1979 Nov;26(5):611-7. doi: 10.1002/cpt1979265611.
2
Role of the gut flora in the reduction of sulfinpyrazone in humans.
J Pharmacol Exp Ther. 1984 Sep;230(3):726-32.
3
Kinetics and metabolism of sulfinpyrazone.磺吡酮的动力学与代谢
Clin Pharmacol Ther. 1983 Apr;33(4):491-7. doi: 10.1038/clpt.1983.67.
4
Sulfinpyrazone and postoperative deep vein thrombosis.磺吡酮与术后深静脉血栓形成
Eur Surg Res. 1977;9(5):303-10. doi: 10.1159/000127949.
5
Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.单次给药后及稳态期间苯磺唑酮及其两种代谢物的血浆水平。
Eur J Clin Pharmacol. 1983;24(2):231-5. doi: 10.1007/BF00613823.
6
New metabolites of sulfinpyrazone in man.
Arzneimittelforschung. 1980;30(6):989-93.
7
[Relative bioavailability study of sulfinpyrazone after oral administration (author's transl)].口服给药后磺吡酮的相对生物利用度研究(作者译)
J Pharm Belg. 1981 Mar-Apr;36(2):81-90.
8
Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.阿地洛尔在健康志愿者单次及多次给药后的药代动力学。
Arzneimittelforschung. 1985;35(6):964-9.
9
Electrophysiologic effects of low dose intravenous sulfinpyrazone in man.低剂量静脉注射磺吡酮对人体的电生理效应。
Proc West Pharmacol Soc. 1982;25:289-91.
10
The effect of aspirin on the pharmacokinetics of sulfinpyrazone in man.阿司匹林对人磺吡酮药代动力学的影响。
Thromb Res Suppl. 1983;4:145-52. doi: 10.1016/0049-3848(83)90370-5.

引用本文的文献

1
Sulphinpyrazone metabolism during long-term therapy.长期治疗期间的磺吡酮代谢
Br J Clin Pharmacol. 1981 Jun;11(6):597-603. doi: 10.1111/j.1365-2125.1981.tb01176.x.
2
Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.单次服用磺吡酮及其主要代谢产物在血浆和尿液中的药代动力学。
Br J Clin Pharmacol. 1982 Feb;13(2):177-85. doi: 10.1111/j.1365-2125.1982.tb01353.x.
3
Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.磺吡酮的临床药代动力学及潜在的重要药物相互作用
Clin Pharmacokinet. 1982 Jan-Feb;7(1):42-56. doi: 10.2165/00003088-198207010-00003.
4
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.磺吡酮:其药理特性与治疗用途综述
Drugs. 1980 Sep;20(3):179-97. doi: 10.2165/00003495-198020030-00002.
5
Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.单次给药后及稳态期间苯磺唑酮及其两种代谢物的血浆水平。
Eur J Clin Pharmacol. 1983;24(2):231-5. doi: 10.1007/BF00613823.
6
Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.慢性治疗期间肾功能损害时磺吡酮的血浆水平及药代动力学:病例报告
Br J Clin Pharmacol. 1984 Jul;18(1):107-8. doi: 10.1111/j.1365-2125.1984.tb05033.x.
7
Sulphinpyrazone increases lymphocyte beta-adrenoceptors in man.磺吡酮可增加人体淋巴细胞的β-肾上腺素能受体。
Br J Clin Pharmacol. 1984 Dec;18(6):963-4. doi: 10.1111/j.1365-2125.1984.tb02572.x.
8
Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.单次给药及长期治疗后磺吡酮及其主要代谢产物的药代动力学
Eur J Clin Pharmacol. 1985;28(1):97-103. doi: 10.1007/BF00635715.
9
Renal clearance of sulphinpyrazone in man.磺胺吡唑酮在人体中的肾脏清除率。
Eur J Clin Pharmacol. 1986;31(4):473-8. doi: 10.1007/BF00613527.
10
Guide to drug dosage in renal failure.肾衰竭药物剂量指南。
Clin Pharmacokinet. 1988 Nov;15(5):326-54. doi: 10.2165/00003088-198815050-00005.